CDXC250117P11000
- 0.00
- 0.000.00%
ChromaDex Newsroom
ChromaDex Corporation's (NASDAQ:CDXC) 28% Cheaper Price Remains In Tune With Revenues
Even Though ChromaDex (NASDAQ:CDXC) Has Lost US$73m Market Cap in Last 7 Days, Shareholders Are Still up 389% Over 1 Year
Analysts Offer Insights on Healthcare Companies: Chromadex (CDXC) and Sagimet Biosciences, Inc. Class A (SGMT)
Ladenburg Thalmann Maintains ChromaDex(CDXC.US) With Buy Rating, Raises Target Price to $6.8
Roth MKM Maintains ChromaDex(CDXC.US) With Buy Rating, Maintains Target Price $8
Unwarranted Negative Reaction to ChromaDex 8-K a Buying Opportunity, Says Roth
ChromaDex 8-K 'May Have Been Misconstrued' by Market, Says Ladenburg
An Intrinsic Calculation For ChromaDex Corporation (NASDAQ:CDXC) Suggests It's 21% Undervalued
AppLovin, MicroStrategy, and 28 Other Stocks That Could Be Bubbles
ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category
Insider Purchase: Chief Financial Officer of $CDXC (CDXC) Buys 2,907 Shares
Recent Price Trend in ChromaDex (CDXC) Is Your Friend, Here's Why
ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement
Express News | Watching ChromaDex; Traders Circulate Stock Picked By Zacks Under $10 Newsletter
We Think ChromaDex's (NASDAQ:CDXC) Profit Is Only A Baseline For What They Can Achieve
ChromaDex's Pharmaceutical-Grade Niagen IV Now Accessible at Over 200 Restore Hyper Wellness Clinics Nationwide
Shareholders Can Be Confident That ChromaDex's (NASDAQ:CDXC) Earnings Are High Quality
Roth MKM Maintains ChromaDex(CDXC.US) With Buy Rating, Raises Target Price to $8
ChromaDex Corporation (CDXC) Hit a 52 Week High, Can the Run Continue?
ChromaDex Analyst Ratings